Latest Tyrosine-kinase inhibitor Stories
LONDON, May 13, 2015 /PRNewswire/ -- INTRODUCTIONOver decades, the oncology market has been led by surgery, chemotherapy and radiotherapy.
DUBLIN, May 13, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/42hpkb/nontyrosine) has announced the addition of the "Non-Tyrosine
DUBLIN, April 14, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/vktrnv/tyrosine_kinase) has announced the addition of the "Tyrosine
Research Presented at 2015 Gastrointestinal Cancers Symposium Highlights Clinical Utility of Caris Molecular Intelligence IRVING, Texas, Jan.
WOODCLIFF LAKE, N.J., Oct. 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S.
FLINT, Mich., Sept.
The Upcoming Entry of New Generation TKIs will Challenge the Established Position of CML Treatments in Brazil and Mexico, According to Findings from Decision Resources Group BURLINGTON, Mass.,
High Cost and High Expectations for Clinical Benefits are Major Market Access Hurdles Facing New CML Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., June 2,
Robust Value Dossiers and Smart Uptake Strategies are Vital to Secure Optimal Market Access in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., May 27, 2014 /PRNewswire/
FLINT, Mich., May 23, 2014 /PRNewswire-iReach/ -- Diplomat, the nation's largest independent specialty pharmacy, announced that it will be distributing SYNRIBO(®) (omacetaxine mepesuccinate),
- A hairdresser.